Table 4.
Treatment Outcomes of the Mesh and Thermo-Expandable Stent Groups
| Mesh (n = 25) | Thermo-expandable (n = 21) | |||
|---|---|---|---|---|
| Primary | Overall | Primary | Overall | |
| Follow-up monthsa | 41.4 ± 23.1 | 34.4 ± 16.5 | ||
| Success rateb, n (%) | ||||
| First year (%) | 13 (54.9) | 18 (78.7) | 14 (70.4) | 15 (75.4) |
| Second year (%) | 4 (16.9) | 10 (54.5) | 11 (59.5) | 12 (64.6) |
| Third year (%) | 4 (16.9) | 9 (49.1) | 4 (30.6) | 7 (56.5) |
| Time to 50% failure (month) | 15.6 | 29.0 | 30.9 | 54.3 |
| Cause of failure, n (%) | ||||
| Patency-related failure | ||||
| Migration | 4 (16.0) | 4 (16.0) | 2 (9.5) | 1 (4.8) |
| Hyperplasia | 14 (56.0) | 5 (20.0) | 3 (14.3) | 5 (23.8) |
| Encrustation | 1 (4.0) | 2 (8.0) | 9 (42.9) | 3 (14.3) |
| Patency-unrelated failure | ||||
| Concomitant changec | 0 (0.0) | 0 (0.0) | 1 (4.8) | 0 (0.0) |
| Fistula | 2 (8.0) | 3 (12.0) | 0 (0.0) | 0 (0.0) |
| Pseudoaneurysm | 1 (4.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) |
aFollow-up months for the two groups were comparable (p = 0.250)
bSuccess rate is an estimate, and the standard error is omitted. Neither the primary nor the overall rates were statistically significant (p = 0.204, 0.586)
cConcomitant change refers to the exchange of one obstructed stent as well as the other unobstructed stent due to concerns over future obstruction